8-K: Mirum Pharma Raises 2025 Revenue Guidance on Strong Q2

Mirum Pharmaceuticals reported strong second quarter 2025 financial results, with total revenue of $127.8 million, and raised its full-year 2025 revenue guidance to $490 million to $510 million.

Summary

• Total revenue for the second quarter ended June 30, 2025, was $127.8 million, compared to $77.9 million for the same period in 2024.
• LIVMARLI net product sales reached $88.2 million in Q2 2025, representing 87% growth over Q2 2024.
• Bile Acid Medicines net product sales were $39.6 million in Q2 2025, a 30% increase over Q2 2024.
• Full-year 2025 revenue guidance has been increased to $490 million to $510 million.
• Total operating expenses for Q2 2025 were $132.8 million, up from $102.1 million in Q2 2024.
• The net loss for Q2 2025 was $(5.861) million, a significant improvement from a net loss of $(24.638) million in Q2 2024.
• As of June 30, 2025, unrestricted cash, cash equivalents, and investments totaled $321.7 million, an increase from $292.8 million at December 31, 2024.
• The company launched the LIVMARLI single oral tablet dose in the U.S. in June.
• Key pipeline milestones include expected topline data for the Volixibat VISTAS study in PSC in Q2 2026, and completion of enrollment for the Volixibat VANTAGE study in PBC and LIVMARLI EXPAND Phase 3 study in 2026.
• A Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) is expected to initiate in the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong commercial performance, significant revenue growth, and an increased full-year revenue guidance. The company also has a robust pipeline with multiple late-stage milestones approaching, supported by a healthy cash balance. While still reporting a net loss, it has significantly narrowed compared to the prior year, indicating progress towards profitability. The overall tone and financial results are very positive.

Positives

• Strong Q2 2025 total revenue of $127.8 million, a substantial increase from $77.9 million in Q2 2024.
• Full-year 2025 revenue guidance was raised to $490 million $510 million, reflecting confidence in continued commercial momentum.
• LIVMARLI net product sales grew 87% year-over-year to $88.2 million, driven by notable outperformance from international business and the U.S. PFIC launch.
• Bile Acid Medicines net product sales increased 30% year-over-year to $39.6 million.
• The net loss significantly narrowed to $(5.861) million in Q2 2025 from $(24.638) million in Q2 2024, indicating improved financial efficiency.
• Maintained a strong balance sheet with $321.7 million in unrestricted cash, cash equivalents, and investments as of June 30, 2025.
• Advancing multiple late-stage clinical milestones for 2026, including anticipated topline data for Volixibat VISTAS study in PSC.
• Volixibat has been granted Breakthrough Therapy Designation for the treatment of PBC.

Negatives

• The company continues to report a net loss, albeit significantly reduced, of $(5.861) million for Q2 2025.
• Total operating expenses increased to $132.8 million in Q2 2025 from $102.1 million in Q2 2024, reflecting increased investment in research and development and selling, general, and administrative activities.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties inherent in the business.
• The company's business is subject to general risks and uncertainties, as well as the impact of geopolitical and macroeconomic events.
• LIVMARLI can cause side effects, including liver injury (which can be serious or lead to liver transplant or death in PFIC patients), stomach and intestinal problems (such as diarrhea and stomach pain), and worsening of Fat Soluble Vitamin (FSV) Deficiency.
• CHOLBAM treatment may lead to exacerbation of liver impairment, and concurrent elevations of serum gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) may indicate overdose.
• CTEXLI can cause liver injury, requiring monitoring of liver function during treatment.

Future Outlook

Mirum Pharmaceuticals expects continued strong commercial performance, particularly from its international business and U.S. PFIC launch, leading to increased full-year 2025 revenue guidance of $490 million to $510 million. The company is also advancing its pipeline with three important late-stage clinical milestones anticipated in 2026, including topline data for the Volixibat VISTAS study in PSC in Q2 2026, and completion of enrollment for the Volixibat VANTAGE study in PBC and LIVMARLI EXPAND Phase 3 study in 2026. A Phase 2 study for MRM-3379 in Fragile X Syndrome is expected to initiate in Q4 2025.

Management Comments

• "Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch."
• "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients than we initially projected, allowing us to raise guidance with confidence."
• "We are carrying that same momentum into our pipeline, where we are on course for three important late stage clinical milestones in 2026."
• "Notably, the VISTAS study of volixibat in PSC will complete enrollment this quarter, and we plan to report topline data in the second quarter of next year."

Industry Context

Mirum Pharmaceuticals operates in the rare disease biopharmaceutical sector, specifically focusing on cholestatic liver diseases and other rare genetic disorders. The strong commercial performance of LIVMARLI and other bile acid medicines, coupled with an expanded revenue guidance, indicates a robust market position and successful commercialization strategy within this niche. The advancement of multiple late-stage pipeline assets, particularly IBAT inhibitors like volixibat, aligns with a broader industry trend of developing targeted therapies for rare conditions with high unmet medical needs. The company's focus on conditions like Alagille syndrome, PFIC, PSC, PBC, and Fragile X Syndrome positions it within a high-growth segment of the pharmaceutical industry, where orphan drug designations often lead to market exclusivity and premium pricing.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to benchmark against.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, increased guidance, and pipeline progress, potentially leading to increased share value. Reduced net loss indicates improved financial health.
• Patients: Positive impact as LIVMARLI is reaching more patients globally, and pipeline advancements (Volixibat, MRM-3379) promise new treatments for rare cholestatic conditions and Fragile X Syndrome.
• Employees: Continued growth and pipeline advancement suggest job stability and potential for expansion.
• Creditors: Improved financial performance and strong cash position enhance the company's ability to meet its financial obligations.

Next Steps

• Host a conference call on August 6, 2025, to provide business updates.
• Initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in the fourth quarter of 2025.
• Complete enrollment for Volixibat VISTAS study in PSC in Q3 2025.
• Report topline data for Volixibat VISTAS study in PSC in the second quarter of 2026.
• Complete enrollment for Volixibat VANTAGE study in PBC in 2026.
• Complete enrollment for LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions in 2026.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution, evidenced by significant revenue growth for its approved products, particularly LIVMARLI, and a substantial increase in full-year revenue guidance. The strong cash position provides financial flexibility to advance a promising late-stage pipeline, which includes multiple potential catalysts in 2026. The narrowing net loss indicates a positive trajectory towards profitability. These factors, combined with the high unmet medical need in the rare disease space, suggest strong future growth potential and make it an attractive investment.

Keywords

Mirum Pharmaceuticals, MIRM, rare diseases, cholestatic liver diseases, Alagille syndrome, PFIC, LIVMARLI, maralixibat, IBAT inhibitor, volixibat, primary sclerosing cholangitis, PSC, primary biliary cholangitis, PBC, CHOLBAM, CTEXLI, Fragile X Syndrome, Q2 2025 earnings, revenue guidance, clinical trials, drug development